{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Gliomas&page=12",
    "query": {
      "condition": "Mixed Gliomas",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 286,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Gliomas&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Gliomas&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T08:09:25.092Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00049127",
      "title": "Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Anaplastic Oligodendroglioma",
        "Adult Mixed Glioma",
        "Adult Oligodendroglioma",
        "Recurrent Adult Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2003-06",
      "completion_date": "2019-09-01",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 229,
      "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 137 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Aurora",
          "state": "Illinois"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049127"
    },
    {
      "nct_id": "NCT01125800",
      "title": "A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Medulloblastoma",
        "Rhabdomyosarcoma",
        "Neuroblastoma",
        "Hepatoblastoma",
        "Glioma",
        "Astrocytoma"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Months to 18 Years"
      },
      "enrollment_count": 76,
      "start_date": "2011-02",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-20",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125800"
    },
    {
      "nct_id": "NCT00019630",
      "title": "Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Soft Tissue Sarcoma",
        "Childhood Liver Cancer",
        "Bone Cancer",
        "Brain Tumor",
        "Kidney Tumor"
      ],
      "interventions": [
        {
          "name": "doxorubicin HCl liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019630"
    },
    {
      "nct_id": "NCT03213665",
      "title": "Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Hodgkin Lymphoma",
        "Ann Arbor Stage III Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Hodgkin Lymphoma",
        "Ann Arbor Stage IV Non-Hodgkin Lymphoma",
        "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Low Grade Glioma",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Hodgkin Lymphoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Rhabdoid Tumor",
        "Refractory Soft Tissue Sarcoma",
        "Rhabdoid Tumor",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2017-11-13",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 115,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213665"
    },
    {
      "nct_id": "NCT00623077",
      "title": "MT2004-30: Tomotherapy for Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Kidney Cancer",
        "Liver Cancer",
        "Retinoblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "tomotherapy",
          "type": "RADIATION"
        },
        {
          "name": "total marrow irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Whole lung radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2005-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623077"
    },
    {
      "nct_id": "NCT00179803",
      "title": "Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Astrocytoma",
        "Pineoblastoma",
        "Rhabdoid Tumor",
        "Supratentorial Neoplasms"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "18 Months to 25 Years"
      },
      "enrollment_count": 24,
      "start_date": "1998-03",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2020-08-05",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179803"
    },
    {
      "nct_id": "NCT00019019",
      "title": "Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Breast Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Lymphoma",
        "Melanoma (Skin)",
        "Ovarian Cancer",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "carboxyamidotriazole",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "1994-10",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019019"
    },
    {
      "nct_id": "NCT07087002",
      "title": "GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Medulloblastoma",
        "Central Nervous System Embryonal Tumor",
        "Refractory Medulloblastoma",
        "Recurrent Medulloblastoma",
        "Pediatric Brain Tumor",
        "Embryonal Tumor With Multilayered Rosettes (ETMR)",
        "Pineoblastoma",
        "Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS",
        "CNS Neuroblastoma",
        "FOXR2-activated",
        "Childhood"
      ],
      "interventions": [
        {
          "name": "GPC2-CAR T cells",
          "type": "GENETIC"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 18,
      "start_date": "2025-08-28",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07087002"
    },
    {
      "nct_id": "NCT02967380",
      "title": "Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Anaplastic (Malignant) Meningioma",
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Choroid Plexus Neoplasm",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoblastoma",
        "Adult Ependymoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Grade II Meningioma",
        "Adult Medulloblastoma",
        "Adult Mixed Glioma",
        "Adult Oligodendroglioma",
        "Adult Papillary Meningioma",
        "Adult Pineal Gland Astrocytoma",
        "Adult Pineoblastoma",
        "Adult Primary Melanocytic Lesion of Meninges",
        "Adult Supratentorial Primitive Neuroectodermal Tumor",
        "Malignant Adult Intracranial Hemangiopericytoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Multiple Sclerosis",
        "Recurrent Adult Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Gadobenate Dimeglumine",
          "type": "DRUG"
        },
        {
          "name": "Gadobutrol",
          "type": "DRUG"
        },
        {
          "name": "Gadopentetate Dimeglumine",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2011-12-14",
      "completion_date": "2015-10-14",
      "has_results": false,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02967380"
    },
    {
      "nct_id": "NCT03213704",
      "title": "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Larotrectinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 9,
      "start_date": "2017-08-23",
      "completion_date": "2027-10-20",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-17T08:09:25.092Z",
      "location_count": 122,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213704"
    }
  ]
}